Subscribe
istock-629794242xesai-1
Xesai / iStockphoto.com
2 August 2018Americas

Patent abuse driving high drug prices, non-profit claims

Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge (I-MAK).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK
20 September 2022   Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.
Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK
20 September 2022   Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.
Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

More on this story

Americas
‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK
20 September 2022   Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.
Americas
PTAB shoots down tenth I-MAK Gilead challenge
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.

More features

Sanofi unit loses genetic disorder patent at EPO after trio of challenges
INTA confirms London as host city for Annual Meeting 2026
INTA unveils key principles on AI and IP rights at Annual Meeting
Illumina takes aim at rival in gene sequencing spat
Novartis tops Big Pharma in global trademark portfolios
PierFerd hires partner with medtech expertise
NanoString to pay 10x Genomics $68m in global settlement
Federal Circuit revives CRISPR feud citing PTAB errors